IPG-DONEPEZIL TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
29-10-2019
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
DONEPEZIL HYDROCHLORIDE
제공처:
MARCAN PHARMACEUTICALS INC
ATC 코드:
N06DA02
INN (국제 이름):
DONEPEZIL
복용량:
5MG
약제 형태:
TABLET
구성:
DONEPEZIL HYDROCHLORIDE 5MG
관리 경로:
ORAL
패키지 단위:
30/100/500
처방전 유형:
Prescription
치료 영역:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
제품 요약:
Active ingredient group (AIG) number: 0131548001; AHFS:
승인 상태:
APPROVED
승인 날짜:
2016-07-29
제품 특성 요약
Page 1 of 50
PRODUCT MONOGRAPH
Pr
IPG-DONEPEZIL
Donepezil Hydrochloride Tablets, House Std
5 and 10 mg
CHOLINESTERASE INHIBITOR
Marcan Pharmaceuticals Inc. Date of Revision:
2 Gurdwara Road, Suite #112
October 23, 2019
Ottawa, ON, K2E 1A2
Control # 226276
Page 2 of 50
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
3
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND ADMINISTRATION
.............................................................................
17
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
22
PHARMACEUTICAL INFORMATION
.........................................................................
22
CLINICAL TRIALS
.........................................................................................................
24
DETAILED PHARMACOLOGY
....................................................................................
전체 문서 읽기
